Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
Saved in:
| Title: | Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. |
|---|---|
| Authors: | Peters S; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch., Paz-Ares LG; Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain., Reck M; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany., Carbone DP; Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center and the Pelotonia Institute for Immuno-Oncology, Columbus, Ohio., Brahmer JR; Department of Oncology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Borghaei H; Hematology and Oncology Department, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania., Lu S; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China., O'Byrne KJ; Department of Medical Oncology, Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia., John T; Medical Oncology Department, Austin Hospital, Heidelberg, Victoria, Australia., Ciuleanu TE; Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania., Schenker M; Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania., Bernabe Caro R; Medical Oncology Department, Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Cobo M; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain., Lee JS; Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Zurawski B; Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland., Pluzanski A; Department of Lung Cancer and Chest Tumours, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Aoyama T; Clinical Development, Bristol Myers Squibb, Princeton, New Jersey., Tschaika M; Global Clinical Research Oncology, Bristol Myers Squibb, Princeton, New Jersey., Devas V; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey., Grootendorst DJ; Translational Sciences Oncology Imaging, Bristol Myers Squibb, Princeton, New Jersey., Ramalingam SS; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Jan; Vol. 20 (1), pp. 94-108. Date of Electronic Publication: 2024 Oct 04. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39369790 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Peters+S%22">Peters S</searchLink>; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.<br /><searchLink fieldCode="AU" term="%22Paz-Ares+LG%22">Paz-Ares LG</searchLink>; Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Reck+M%22">Reck M</searchLink>; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany.<br /><searchLink fieldCode="AU" term="%22Carbone+DP%22">Carbone DP</searchLink>; Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center and the Pelotonia Institute for Immuno-Oncology, Columbus, Ohio.<br /><searchLink fieldCode="AU" term="%22Brahmer+JR%22">Brahmer JR</searchLink>; Department of Oncology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Borghaei+H%22">Borghaei H</searchLink>; Hematology and Oncology Department, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Lu+S%22">Lu S</searchLink>; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22O'Byrne+KJ%22">O'Byrne KJ</searchLink>; Department of Medical Oncology, Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22John+T%22">John T</searchLink>; Medical Oncology Department, Austin Hospital, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Ciuleanu+TE%22">Ciuleanu TE</searchLink>; Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania.<br /><searchLink fieldCode="AU" term="%22Schenker+M%22">Schenker M</searchLink>; Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania.<br /><searchLink fieldCode="AU" term="%22Bernabe+Caro+R%22">Bernabe Caro R</searchLink>; Medical Oncology Department, Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Nishio+M%22">Nishio M</searchLink>; Department of Thoracic Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Cobo+M%22">Cobo M</searchLink>; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.<br /><searchLink fieldCode="AU" term="%22Lee+JS%22">Lee JS</searchLink>; Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Zurawski+B%22">Zurawski B</searchLink>; Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland.<br /><searchLink fieldCode="AU" term="%22Pluzanski+A%22">Pluzanski A</searchLink>; Department of Lung Cancer and Chest Tumours, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Aoyama+T%22">Aoyama T</searchLink>; Clinical Development, Bristol Myers Squibb, Princeton, New Jersey.<br /><searchLink fieldCode="AU" term="%22Tschaika+M%22">Tschaika M</searchLink>; Global Clinical Research Oncology, Bristol Myers Squibb, Princeton, New Jersey.<br /><searchLink fieldCode="AU" term="%22Devas+V%22">Devas V</searchLink>; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey.<br /><searchLink fieldCode="AU" term="%22Grootendorst+DJ%22">Grootendorst DJ</searchLink>; Translational Sciences Oncology Imaging, Bristol Myers Squibb, Princeton, New Jersey.<br /><searchLink fieldCode="AU" term="%22Ramalingam+SS%22">Ramalingam SS</searchLink>; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101274235%22">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</searchLink> [J Thorac Oncol] 2025 Jan; Vol. 20 (1), pp. 94-108. <i>Date of Electronic Publication: </i>2024 Oct 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101274235 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1556-1380 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215560864%22">15560864 </searchLink><i>NLM ISO Abbreviation: </i>J Thorac Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39369790 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.jtho.2024.09.1439 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 94 Titles: – TitleFull: Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Peters S – PersonEntity: Name: NameFull: Paz-Ares LG – PersonEntity: Name: NameFull: Reck M – PersonEntity: Name: NameFull: Carbone DP – PersonEntity: Name: NameFull: Brahmer JR – PersonEntity: Name: NameFull: Borghaei H – PersonEntity: Name: NameFull: Lu S – PersonEntity: Name: NameFull: O'Byrne KJ – PersonEntity: Name: NameFull: John T – PersonEntity: Name: NameFull: Ciuleanu TE – PersonEntity: Name: NameFull: Schenker M – PersonEntity: Name: NameFull: Bernabe Caro R – PersonEntity: Name: NameFull: Nishio M – PersonEntity: Name: NameFull: Cobo M – PersonEntity: Name: NameFull: Lee JS – PersonEntity: Name: NameFull: Zurawski B – PersonEntity: Name: NameFull: Pluzanski A – PersonEntity: Name: NameFull: Aoyama T – PersonEntity: Name: NameFull: Tschaika M – PersonEntity: Name: NameFull: Devas V – PersonEntity: Name: NameFull: Grootendorst DJ – PersonEntity: Name: NameFull: Ramalingam SS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2025 Jan Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1556-1380 Numbering: – Type: volume Value: 20 – Type: issue Value: 1 Titles: – TitleFull: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Type: main |
| ResultId | 1 |
